Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions

Distal Urethral Cancer | Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Proximal Urethral Cancer | Recurrent Bladder Cancer | Recurrent Prostate Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Urethral Cancer | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage IV Bladder Cancer | Stage IV Prostate Cancer | Stage IV Urethral Cancer | Transitional Cell Carcinoma of the Bladder | Ureter Cancer | Urethral Cancer Associated With Invasive Bladder Cancer

What is the purpose of this trial?

This randomized phase III trial studies gemcitabine hydrochloride, cisplatin, and bevacizumab to see how well they work compared with gemcitabine hydrochloride and cisplatin in treating patients with urinary tract cancer that has spread to other places in the body. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether gemcitabine hydrochloride and cisplatin are more effective when given together with or without bevacizumab in treating patients with urinary tract cancer.



Participation Guidelines

Age:
18 Years - N/A
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
National Cancer Institute (NCI)
Dates:
July 2009
Last Updated:
September 2, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT00942331